Skip Navigation



Cardiovascular Research Advance Access [Accepted Manuscript] published online on December 4, 2007

Cardiovascular Research, doi:10.1093/cvr/cvm083
This Article
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
77/4/757    most recent
cvm083v2
cvm083v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Bruce, A. F
Right arrow Articles by Severs, N. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bruce, A. F
Right arrow Articles by Severs, N. J
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Gap junction remodeling in human heart failure is associated with increased interaction of connexin43 with ZO-1

Alexandra F Bruce, Stephen Rothery, Emmanuel Dupont and Nicholas J Severs*

National Heart and Lung Institute, Imperial College London

* Corresponding author: Nicholas J Severs, Cardiac Medicine, National Heart & Lung Institute, Imperial College London, Guy Scadding Building, Dovehouse Street, London SW3 6LY, UK. E-mail n.severs{at}imperial.ac.uk; Tel +44(0)2073518140; Fax +44(0)2073518476

Aims: Remodeling of gap junctions, involving reduction of total gap junction quantity and down-regulation of connexin43 (Cx43), contributes to the arrhythmic substrate in congestive heart failure. However, little is known of the underlying mechanisms. Recent studies from in vitro systems suggest that the connexin-interacting protein zonula occludens-1 (ZO-1) is a potential mediator of gap junction remodeling. We therefore examined the hypothesis that ZO-1 contributes to reduced expression of Cx43-gap junctions in congestive heart failure.

Methods and results: Left ventricular myocardium from healthy control human hearts (n=5) was compared with that of explanted hearts from transplant patients with end-stage congestive heart failure due to idiopathic dilated cardiomyopathy (DCM; n=5) or ischemic cardiomyopathy (ICM; n=5). Immunoconfocal and immuno-electron microscopy showed that ZO-1 is specifically localized to the intercalated disk of cardiomyocytes in control and failing ventricles. ZO-1 protein levels were significantly increased in both DCM and ICM (P=0.0025), showing a significant, negative correlation to Cx43 levels (P=0.0029). There was, however, no significant alteration of ZO-1 mRNA (P=0.537). Double immunolabeling demonstrated that a proportion of ZO-1 label is co-localized with Cx43, and that co-localization of Cx43 with ZO-1 is significantly increased in the failing ventricle (P=0.003). Interaction between the two proteins was confirmed by co-immunoprecipitation. The proportion of Cx43 that co?immunoprecipitates with ZO-1 was significantly increased in the failing heart.

Conclusion: Our findings suggest that ZO-1, by interacting with Cx43, plays a role in the down-regulation and decreased size of Cx43 gap junctions in congestive heart failure.


Time for primary review: 15


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
N. J. Severs, A. F. Bruce, E. Dupont, and S. Rothery
Remodelling of gap junctions and connexin expression in diseased myocardium
Cardiovasc Res, October 1, 2008; 80(1): 9 - 19.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.